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Context: Surgical intervention is advised in patients with multiple endocrine neoplasia type-1 
(MEN-1) with non-functioning pancreatic neuroendocrine tumors (PanNET) and a size 
≥20mm. Functioning PanNET such as patients with endogen us hyperinsulinemic 
hypoglycemia (EHH) due to (one or multiple) insulinoma(s) should be treated surgically 
independent of size. Preoperative localization of insulinomas is critical for surgery.  
Objective: To evaluate feasibility and sensitivity of 68Ga-DOTA-exendin-4 PET/CT in the 
detection of clinical-relevant lesions in MEN-1 patients with EHH in combination with MRI. 
Design: Post-hoc subgroup-analysis of a larger prospective imaging study with 52 EHH 
patients. 
Patients: Six of 52 consecutive patients with EHH and genetically proven MEN-1 mutation 
were included. 
Interventions: All patients received one 68Ga-DOTA-exendin-4 PET/CT and one MRI-scan 
within 3-4 days. Thereafter, surgery was performed based on all imaging results. 
Main Outcome Measures: Lesion-based sensitivity of PET/CT and MRI for detection of 
clinical-relevant lesions was calculated. Readers were unaware of other results. Reference 
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standard was surgery with histology and treatment outcome. True positive (=clinical-relevant 
lesions) was defined as PanNET ≥20mm or insulinoma. 
Results: In six patients, 37 PanNET were confirmed by histopa hology. Sensitivity (95% 
confidence interval) in the detection of clinical-re evant lesions for combined PET/CT+MRI, 
MRI and PET/CT was 92.3% (64%-99.8%), 38.5% (13.9-68.4%) and 84.6% (54.6-98.1%), 
respectively (P-value=0.014 for the comparison of PET/CT+MRI versus MRI). Post-surgery, 
EHH resolved in all patients.   
Conclusion: 68Ga-DOTA-exendin-4 PET/CT is feasible in MEN-1 patients with EHH. The 
combination with MRI is superior to MRI alone in the detection of insulinomas and may 
guide the surgical strategy. 
Evaluating the feasibility and sensitivity of 68Ga-exendin-4 PET/CT in the detection of relevant lesions 
in MEN-1 patients with hypogylcemia in comparison with magnetic resonance imaging (MRI). 
Introduction 
Multiple endocrine neoplasia type 1 (MEN-1) is an autosomal dominant inherited tumor 
syndrome caused by heterozygous mutations in the MEN-1 tumor suppressor gene with an 
incidence of 1:50,000. More than 80% of these patients develop multifocal functioning (F-
PanNET) or non-functioning pancreatic neuroendocrine tumors (NF-PanNET), which are a 
major cause of premature death due to malignant progression (1,2). The most common F-
PanNETs in MEN-1 are duodenal gastrinomas causing Zollinger Ellison Syndrom and 
pancreatic insulinomas causing endogenous hyperinsulinemic hypoglycemia (EHH)(3). 
Insulinomas can cause life threatening EHH and surgery is the cornerstone of therapy as 
current medical treatments remain insufficient, do not provide a permanent cure, and thus 
should be reserved for the perioperative period or for patients who cannot undergo surgery 
(4).  
Older studies have proposed aggressive resection of every tumor identified by 
conventional imaging studies in the presence of biochemically proven EHH (5-7). However, 
pancreatic surgery is associated with significant mortality and long-term morbidity (8,9). NF-
PanNET < 20 mm rarely develop metastases (10,11), and current studies have not shown any 
survival benefit for patients with NF-PanNET ≤ 20 mm who received surgery in comparison 
to patients who had conservative management, i.e. watchful waiting (12). Consequently, in 
patients with non-metastatic pancreatic neuroendocrine tumors (PanNET) all international 
guidelines recommend the resection of symptomatic insul nomas with the aim of eliminating 
life-threatening endogenous hyperinsulinemic hypoglycemia, but resection of NF-PanNET 
only above a size ≥20 mm due to the increased risk for malignant progression (12-14). For 
NF-PanNET <20 mm, the all international guidelines suggest a conservative management 
strategy (13).  
In clinical routine different imaging modalities are used for the localization of 
insulinomas: contrast-enhanced computed tomography (CT), contrast-enhanced magnetic 
resonance imaging (MRI) (which is more sensitive than CT for this indication (15,16)), 
endoscopic ultrasound (EUS) and somatostatin receptor imaging (Octreoscan® or 68Ga-
DOTATOC/68Ga-DOTATATE/68Ga-DOTANOC PET/CT). Especially in the context of 
MEN-1, when multiple other PanNET are detected, these inv stigations remain insufficient 
due to mainly two reasons. First, the small size of insulinomas (usually < 20 mm at 
presentation (15,17)) makes them susceptible to motion artefacts, such as respiratory motion, 
cardiac pulsation and bowel peristalsis, and thus limits their detectability (18). Secondly 
morphological imaging as well as somatostatin receptor imaging is not able to differentiate 
insulinomas from NF-PanNETs. To regionalize an insuli oma calcium stimulations test is 
recommended to avoid "blind" pancreatic resections (19,20). 
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In general, gastroenteropancreatic neuroendocrine neoplasms are known to overexpress 
the somatostatin receptor subtype 2 at a high density i  70%-100% of the cases, except in 
benign insulinomas where the expression is lower. Glucagon-like peptide-1 receptors (GLP-
1R), on the other hand are expressed at high density i  sporadic insulinomas (21). Exendin-4 
is a synthetic US Food U.S.Food and Drug Administration (FDA) approved glucagon-like 
peptide-1 (GLP-1) analog primarily established for the treatment of type 2 diabetes mellitus 
targeting GLP-1R. The GLP-1 pathway is important in islet regeneration (22,23) by 
regulating inhibition of β-cell apoptosis (24) and stimulation of β-cell proliferation and 
insulin secretion. Previous studies have shown that GLP-1R imaging can be used as a very 
sensitive, non-invasive method to localize benign sporadic insulinomas using radiolabeled 
exendin-4 SPECT/CT or PET/CT (25-31), where GLP-1R PET/CT performs significantly 
better than SPECT/CT (28). Nonetheless, as opposed t  benign insulinomas, malignant 
insulinomas often lack the GLP-1 receptors and conversely often overexpress the 
somatostatin type 2 receptor (32).  
In the context of MEN-1, the biological characteristics (benign or malignant) of insulin-
secreting neuroendocrine tumors (NET) is not well explored. A recent study with GLP-1R 
imaging using 68Ga-DOTA-exendin-4 PET/CT in heterozygous MEN-1 knockout mice 
demonstrated its potential for lesion detection in the MEN-1 pancreas(33). This was related to 
increased GLP-1R expression in early tumorigenesis. However, in humans with MEN-1 and 
EHH, in vivo or in vitro GLP-1R expression has not been examined as yet. In view of the 
always multiple PanNETs visualized on conventional imaging in the context of MEN-1 
patients, the exact localization of the insulin-secreting PanNET is critical for the surgical 
strategy in order to avoid unnecessary morbidity due to extensive surgery.  
In this retrospective analysis, combination of 68Ga-DOTA-exendin-4 ([Nle14,Lys40(Ahx-
DOTA-68Ga)NH2]exendin-4) PET/CT and MRI was analyzed to evaluate its potential role in 
patients with MEN-1 mutations and confirmed EHH. We hypothesized that GLP-1R imaging 
in the context of MEN-1 is feasible and may be able to guide surgical strategy in patients with 
PanNETs in the context of EHH and multiple pancreatic lesions.  
Materials and Methods  
Study design and patients 
Between January 2014 until March 2017, 52 patients with biochemically-proven EHH highly 
suspicious for an insulinoma were prospectively recruited from different centers in Europe 
and the United States of America (ClinicalTrials.gov, NCT02127541). Six of the 52 patients 
(female: 4; male: 2 patients, median age 34.5 [interquartile range 18.8-46] years) were 
identified to have a genetically-proven germline mutation in the MEN1 gene and were 
included in this post-hoc analysis.  
The patients fulfilled the inclusion criteria, whic were age ≥18 years, biochemically-
proven EHH with neuroglycopenic symptoms, a positive Whipple triad and negative results 
on sulfonylurea screening. Exclusion criteria were vidence of a malignant insulinoma on 
conventional imaging, pregnancy or breastfeeding women, and renal insufficiency (serum 
creatinine >140 µmol/L). None of the patients had briatric surgery or other known causes for 
EHH (34).  
The study was approved by the Regional Scientific Ethics Committee and patients 
provided written consent in accordance with provision  of the Declaration of Helsinki prior to 
study participation. 
Procedures 
All patients received one 68Ga-DOTA-exendin-4  PET/CT and a standardized contrast-
enhanced MRI scan within 3-4 days. The reference standard was successful surgery with 
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histopathological and immunohistochemical confirmation of PanNETs including insulinoma 
and normalization of blood glucose levels after surgery.  
PET/CT was performed on different scanners in supine osition: PET/16-detector CT 
scanner (Discovery ST; GE Healthcare), PET/64-detector CT scanner (Discovery ST; GE 
Healthcare), PET/128-detector CT scanner (Biograph mCT-X RT Pro Edition). Calibration of 
PET scanners and their cross calibration was performed. One bed position of the upper 
abdomen was acquired during 8 min, 2.5 h after the intravenous injection of 68Ga-DOTA-
exendin-4. PET images were reconstructed using an ordered-subsets expectation 
maximization (OSEM) algorithm with 3 iterations and 25 subsets. Low-dose CT (120 kVp, 
30–100 mAs) was used in all patients for attenuation c rrection and to provide an anatomic 
reference. 
Abdominal MRI acquisition was performed on a commercially available 3T system 
(Magnetom Prisma, Siemens Healthcare, Erlangen, Germany) in supine position using a 
multichannel body surface coil. The protocol aimed for a high spatial resolution and 
robustness with regard to breathing and motion artefacts. The body surface coil was placed 
firmly across the abdomen and patients were asked to breathe calm and shallow to avoid 
excessive abdominal excursion during breathing.  
The protocol included standard sequences: a) coronal half fourier acquisition single shot 
turbo spin echo (HASTE) localizer b) coronal breath hold T2 weighted HASTE c) transverse 
breath hold T2 weighted HASTE d) transverse, fat suppressed T2 weighted turbo spin echo 
(TSE) images in breath hold e) Breath hold in- and out-of-phase T1-weighted gradient-echo 
sequence f) free breathing echo planar diffusion weight d images in the transverse plane 
using five b values (0, 50, 200, 400, and 800) g) transverse, free breathing (respiratory-
triggered, navigator-echo technique) h) fat suppressed, T2 weighted spin echo sequences 
images using periodically rotated overlapping parallel lines with enhanced reconstruction 
(BLADE). 
Detailed acquisition parameters for non-contrast-enhanced PET/CT and standardized 
contrast-enhanced MRI have been described elsewhere (28).  
Evaluation 
Only the pancreas was regarded as potential tumor site. In order to localize tumors in the 
pancreas in a standardized manner, the pancreas was categorized into three regions, namely, 
head, body, and tail, with the portal vein and the superior mesenteric artery serving as 
anatomic landmarks (Figure 1).  
PET/CT, and MRI scans were independently assessed in a random order, by three board-
certified nuclear medicine physicians for PET/CT scans and three different board-certified 
radiologists for MRI, each with >10 years of experience in PET/CT or MRI reading. All 
readers were unaware of the patients’ identity, other imaging results, or the patient’s clinical 
history. The number of lesions that could be clearly identified as a single focus was 
determined for each patient through majority reading.  
A dual-accredited radiologist/nuclear medicine physician correlated lesions from blinded 
reading of 68Ga-DOTA-exendin-4 PET/CT and standardized contrast enhanced MRI, which 
was used for the sensitivity analysis of combined 68Ga-DOTA-exendin-4 PET/CT and MRI in 
the detection of clinical-relevant lesions. 
A 68Ga-DOTA-exendin-4   PET positive lesion was defined as insulinoma. On contrast-
enhanced MRI a lesion with a clear tumor-to-background ratio visualized in at least 2 
sequences was defined as PanNET (Figure 2).  
 The reference standard for tumor size was from the surgical specimens and from MRI 
imaging.  
68Ga-DOTA-exendin-4    uptake was quantified using maximum standardized uptake 
values (SUVmax). 
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Histopathologic diagnosis was made at the local refer ing institution where surgery was 
performed. In case of controversial findings, central histological reading was available at the 
tertiary institution (Institute of Pathology, University Bern). 
Statistical analysis 
Diagnostic performance in the detection of clinical-relevant lesion was quantified on a per-
lesion basis as sensitivity, specificity and diagnostic accuracy. The reference standard was the 
histopathological diagnosis of surgical-removed tissue. Data were assessed according to 
ENETS recommendation, namely, to resect clinical-relevant lesions, that is insulinomas 
independent of size and (if possible) only NF-PanNET ≥ 20 mm with the aim of a pancreas 
preserving surgery approach (13). Findings were defined as follows:  
For MRI which can measure tumor size but not discriminate between NF-PanNET and 
insulinomas (Figure 3): 
True positive (TP): detected NF-PanNET and Insulinomas ≥ 20 mm 
True negative (TN): all NF-PanNET < 20 mm (defined as clinical not relevant lesion) 
False negative (FN): not detected NF-PanNET and insulinomas ≥ 20 mm; all Insulinomas < 20 mm  
False positive (FP): all detected lesions ≥ 20 mm, which were not confirmed by surgery/histology.  
For 68Ga-DOTA-exendin PET/CT which cannot measure tumor size but can likely 
discriminate between NF-PanNET and Insulinomas (Figure 3): 
TP: detected Insulinoma of any size and detected NF-PanNET ≥ 20 mm 
TN: not detected NF-PanNET < 20 mm 
FN: not detected NF-PanNET ≥ 20 mm and not detected Insulinoma of any size 
FP: detected NF-PanNET < 20 mm 
In case of discordant findings for combined 68Ga-DOTA-exendin-4 PET/CT and MRI i.e. 
TP with one imaging method and FN with the other, the combined finding is rated as TP. 
All analyses were conducted using the statistical software package R (R Core Team, 
2018), Version 3.5.0, using two-sided statistical tests. Confidence intervals are calculated at a 
1-α level of 95%. P values should be interpreted as a continuous measure of evidence against 
the corresponding null-hypothesis (i.e. no difference between imaging methods) and not as 
confirmatory (“significant” vs. “non-significant”). 
Sensitivity, specificity and overall diagnostic accuracy for each imaging method in the 
detection of clinical-relevant lesions were calculated with exact binomial 95 % confidence 
interval using the R package epiR. The imaging methods were tested for a difference in the 
respective measure using mixed-effects logistic regression models (GLMM). 
The models included the respective outcome as binary endpoint (e.g. for sensitivity the 
outcome was TP, 0/1), patient as random effect, and the imaging method as main predictor. 
For the objective of identification of all clinical-relevant tumor findings 68Ga-DOTA-
exendin-4  PET/CT and MRI were compared to both methods combined. P-values for the 
comparisons are reported. No adjustment for multiple testing was made. Cross tabulations of 
the findings based on the imaging methods and the results of histopathology are given. 
Results 
Surgery and histopathological evaluation 
All 6 patients received surgery based on all available imaging results and following the 
recommendations of current international guidelines. Table 1 summarizes the individual 
surgical procedures.  
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In six patients a total of 37 PanNETs were confirmed by histopathology with a median 
number of lesions per patient of 7.5 and interquartile range (IQR) of 2.5-8.5 (see Table 1). 
This included 11 (30%) insulinomas with a median size of 11 mm (range 1-20 mm), 26 
(70%) NF-PanNETs with a median size of 4 mm (range 0.5-25 mm). The tumor grade was 
determined histologically using mitotic rates and Ki-67 indices (European Neuroendocrine 
Tumor Society proposal for grading GEP- NETs) (35) and was available in 25 lesions: 19 
Lesions were classified as G1 tumors and six lesions were classified as G2 tumors. No G3 
tumors were identified. Twenty-two lesions were notde ected by the imaging procedures. 
Median tumor size of all lesions was 6 mm (range 0.5-25 mm). 
Table 2 summarizes the diagnostic performance of 68Ga-DOTA-exendin-4   PET/CT and 
MRI for detection of all clinical-relevant tumor findings.  
Comparison of MRI with histopathology 
MRI reading is based on majority reading by 3 radiologists. In the detection of clinical-
relevant lesions, defined as PanNET ≥ 20mm, MRI showed 5 true positive, 24 true negative, 
8 false negative and 0 false positive findings. MRI did not detect 22 tumors, which had a 
median size of 2.1 mm (range 0.5-17 mm). 
Comparison of 68Ga-DOTA-exendin-4  PET/CT with histopathology 
Lesion detection on 68Ga-DOTA-exendin-4  PET/CT is based on majority reading by 3 
nuclear medicine physicians. SUVmax was determined for all detected insulinomas and 
ranged from 4.3-43 with a median SUVmax (IQR) of 22.4 (9.1-34.9).  
68Ga-DOTA-exendin-4  PET/CT identified 11/37 (30%) tumors with a median size of 14 
mm (range 4-21 mm) of which 10/11 (91%) were insulinomas and 1/11 (9%) was a NF-
PanNET with a diameter of 21 mm. 68Ga-DOTA-exendin-4  PET/CT did not detect 26 
tumors, median size of 4 mm (range 0.5-25 mm). Thisincluded 1/26 (4%) insulinoma (tumor 
size 1mm), 2/26 (8%) and 25/26 (88%) NF-PanNETs (median tumor size 4 mm, range 0.5-25 
mm).  
In the detection of clinical-relevant lesions, 68Ga-DOTA-exendin-4    PET/CT was true 
positive in 11/37 (30%), true negative in 24/37 (65%) and false negative in 2/37 (5%) and 
false positive in 0/37 (0%). 
Surgical strategy and outcome 
Surgical planning was based on all available imaging results and performed in all six patients. 
Symptoms of EHH ceased in all patients after surgery with no recurrence within a follow-up 
period of 3 months. Median time between study imaging and surgery were 3.5 months (IQR 
2.8–9) months.  
Side effects 
Nausea and sporadic vomiting are known side effects of 68Ga-DOTA-exendin-4   and have 
been described elsewhere (28). All patients received an exogenous glucose (1,000 mL, 10%) 
infusion for 5 h starting just before injection of the radiotracer and a flow adapted as needed.  
Discussion 
To our knowledge, this is the first study investigaing the potential role of GLP-1R imaging 
in patients with EHH and a known MEN-1 germline mutation. The main findings of this 
study can be summarized as follows: 1) Overexpression of GLP-1R is present in insulinomas 
in patients with EHH in the context of MEN-1 syndrome and, therefore, GLP-1R imaging is 
feasible and helpful in this context to guide selectiv  and pancreas-sparing surgery. 2) 
Conventional imaging alone may be insufficient as it detects less than half of the pancreatic 
lesions in MEN-1 patients. Combination of 68Ga-DOTA-exendin-4 PET/CT and MRI is 
highly beneficial to detect clinical-relevant lesions in MEN-1 patients as morphological 
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imaging alone cannot differentiate between insulin-secreting between insulin-secreting and 
non-insulin-secreting PanNETs. 
Our data confirm that preoperative GLP-1R PET/CT in the context of a MEN-1 mutation 
is useful. This finding is further substantiated by the fact that in vivo assessment of GLP-1R 
density using SUVmax measurements yielded similar results in MEN-1 insulinomas as seen 
in sporadic benign insulinoma cases, median SUVmax (IQR): 22.4 (9.1-34.9) versus 20 
(12.5-35.3) (28) indicating that insulinomas in thecontext of MEN-1 show a similar GLP-1R 
overexpression. So far this feature has only been proven in conventional heterozygous 
knockout mouse model of Men1 (33). These MEN-1 mice exhibited an overexpression of 
GLP-1R in microadenomas, consistent with our findings in humans and suggesting that 68Ga-
DOTA-exendin-4  has a potential role for the detection of insulinomas in patients with MEN-1 
and EHH. 
On histopathological examination 37 PanNETs were diagnosed in six patients consistent 
with previous histopathological studies (36). Amongst them, 22 lesions were not detected by 
MRI or GLP-1R imaging, mainly because there were not i sulinoma or with a size below 
imaging resolution. The small size of the undetected lesions, the limited spatial resolution of 
MRI as well as the susceptibility to motion artefacts and bowel peristaltic movement, could 
be an explanation as to why the lesions were missed in MRI. However, for the detected 
tumors ≥ 20mm in which according to ENETs guidelines resection due to increased 
malignancy potential is recommended (13), MRI had a sensitivity of 100%.  
Insulin secreting NET in the context of MEN-1 are typically smaller lesions within 
multiple PanNET (36). It is, therefore, highly relevant that, GLP-1R imaging detected 
insulinomas up to a minimal size of 4 mm (Table 1), corroborating the high sensitivity of this 
investigation. In addition, the fact that all six patients were cured of their hypoglycemia 
following surgery suggests that the clinical-relevant insulin-secreting NET were successfully 
treated by GLP-1R imaging guided surgery.  
Morphological assessment of PanNET (i.e. size) in patients with MEN-1 is critical to 
determine the potential for a malignant course of the disease (12). However conventional 
morphological imaging is not able to distinguish between functional and non-functional 
tumors, thus the only criteria justifying resection of a tumor is based on its size. Since 
insulinomas in the context of MEN-1 are often small (36), MRI produces a high number of 
false negative findings (8 lesions)  and a low number of true positive findings (5 lesions) in 
comparison to GLP-1R PET/CT, which showed only 2 false negative findings and a higher 
number of true positive findings (11 lesions) . The combination of both imaging modalities 
reduces the high rate of false negative findings to 1 lesion and increases the rate of true 
positive findings to 12 resulting in a sensitivity of 92.3%. Consequently, in clinical routine 
practice the combination of both modalities is advocated in patients with MEN-1 and EHH. 
Identification of PanNET < 20 mm with native low dose CT was inferior compared to MRI 
(results not shown). However, contrast-enhanced CT in combination with GLP-1R imaging 
as a one stop shot PET/CT  procedure is likely to perform as good as MRI plus GLP-1R PET 
because contrast medium enhanced CT is able to detect and pancreatic neighborhood and the 
lesion threshold size of  ≥ 20 mm should be above the detection limit of contrast-enhanced 
CT. Another alternative is the use of an integrated PET/MRI scanner.  
68Ga-DOTA-exendin-4  PET/CT was positive in one NF-PanNET (patient Nr. 5/tumor Nr. 
22) with high 68Ga-DOTA-exendin-4  uptake (SUVmax of 34.9). The diameter of this tumor 
was 21 mm and MRI detected it as well.  
This is an intriguing finding. It suggests that NF-PanNET can sometimes express the 
GLP-1R at a high density consistent with previous findings in the literature (21). However, 
well differentiated NETs, such as gastrinomas and PPomas were not detected by GLP-1R 
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imaging in this study confirming previous findings, that the GLP-1R receptor is mainly 
overexpressed in insulinomas (21).  
This study has limitations:  
1) It was a retrospective analysis of prospectively collected data. As in all retrospective studies, they are 
prone to possible bias. In particular, there was not always enough reliable data on the intraoperative 
tumor localization. 2) Histological assessment was not a priori centralized and proliferative activity of 
the tumors could have an influence on the overexpression of the GLP-1R (32); this was not evaluated 
in all tumors. Furthermore, an additional limit maybe that positivity for insulin staining is not 
mandatory associated with significant EHH, especially n patients with MEN-1. However, the fact that 
all patients were cured of hypoglycemia following the surgical intervention suggests that the clinical-
relevant lesions were surgically removed. 3) Low-dose native CT scan  is not per se a diagnostic 
procedure, because it is unable to document clearly the size of lesions as well as important anatomical 
structures (e.g. main pancreatic duct) which is important for planning the surgical strategy. In an ideal 
setting contrast-enhanced PET/CT or contrast enhanced PET/MRI should be used.     
In conclusion, GLP-1R PET/CT is a useful and reliable imaging technique to selectively 
identify insulinomas within the multiple  pancreatic NET in patients with MEN-1. The 
careful interpretation of a morphological modality (MRI) in combination with a functional 
imaging technique (GLP-1R PET/CT) may guide the surgical procedure and avoid 
unnecessary pancreatic resections. “Blind” pancreatic resections should be history. 
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FIG 1. Schema of the pancreas which was used for standardized reading by blinded board-
certified nuclear medicine physicians and board certified radiologists.  
FIG. 2. Patient 4 with EHH and 3 suspicious lesions in MRI. (A) Transaxial contrast 
enhanced T1 weighted MRI shows a 20 mm measuring hypointense lesion in the uncinate 
process of the pancreatic head. (B) Transaxial PET/CT 2.5 h after injection of 68Ga-DOTA-
exendin-4  shows an intensive focal uptake in the same lesion. (C) Transaxial diffusion 
weighted MRI shows a 4 mm measuring hyperintense lesion in the pancreatic body which is 
68Ga-DOTA-exendin-4  positive (D). (E)Transaxial T2 weighted MRI shows a 25 mm 
measuring lesion in the pancreatic tail without 68Ga-DOTA-exendin-4  uptake (F). 
Histological evaluation revealed one insulinoma in the uncinated process and pancreatic body 
(both 68Ga-DOTA-exendin-4  PET positive) and a NF-PanNET of 25 mm in the pancreatic 
tail. All other tumors were no insulinomas and smaller than 20 mm and therefore not clinical-
relevant. EHH resolved after surgery. 
FIG. 3. Flowchart with MRI (A) and 68Ga-DOTA-exendin-4 PET/CT (B) reading 
results. According to ENETS guidelines true positive was defined as PanNET ≥20mm or 
insulinoma (=clincal-relevant lesions). Abbreviation: TP = true positive, TN = true 
negative, FP = false positive, FN = false negative, NF-PanNET = non-functioning pancreatic 
neuroendocrine tumor. aMRI is not able to distinguish between functional and non-functional 
tumors, thus the only criteria justifiying resection f tumor in the pancreas is a size of ≥ 20 
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mm. As a result insulinoma < 20 mm are classified as false negative in MRI reading. 
bDiameter measured with MRI 
TABLE 1. Summary of lesion characteristics  
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e 
T
N 
Neg
ative 
TN Body  5 NF-PanNET / Gastrin G1 / 
Ki67 < 
2% 
32 Posi
tive 
T
N 
Neg
ative 
TN Tail  15 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
33 Neg
ativ
e 
T
N 
Neg
ative 
TN Tail  9 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
34 Neg
ativ
e 
T
N 
Neg
ative 
TN Tail  0.8 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
35 Neg
ativ
e 
T
N 
Neg
ative 
TN Tail  1 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
36 Neg
ativ
e 
T
N 
Neg
ative 
TN Tail  1.1 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
37 Neg
ativ
e 
T
N 
Neg
ative 
TN Tail  0.5 NF-PanNET/ ChA/Syn G1 / 
Ki67 < 
2% 
aResults of scan reading. Readers were unaware of other results when reading the scans. bEvaluation according 
to ENETS recommendation with true positive results in case of symptomatic insulinomas and NF-PanNET ≥ 20 
mm. Abbreviation: TP = true positive, TN = true negative, FN = false negative, NF-PanNET = non-functioning 
pancreatic neuroendocrine tumor; NA = not available, ChA = Chromgranin A, Syn= Synaptophysin.  
 
TABLE 2. Comparison of combined 68Ga-DOTA-exendin-4  PET/CT + MRI, 68Ga -exendin-
4 PET/CT and MRI alone in the detection of clinical-relevant PanNET(defined as NF-
PanNET ≥20 mm or insulinomas) in MEN-1 patients with endogenous hyperinsulinemia 
hypoglycemia + neuroglycopenia and multiple pancreatic tumors 
 68Ga-DOTA-exendin-4  
PET/CT + MRI 
68Ga-DOTA-exendin-4  
PET/CT 
Test for 
superioritya 
MRI Test for 
superiorityb 
Clinical-
relevant 
lesion 
Sensitivity  
92.3% [64.0-99.8] 84.6% [54.6-98.1] 0.537 38.5% [13.9-68.4] 0.014 
Clinical-
relevant 
lesion 
100% [85.8-100] 100% [85.8-100] 1.000 100% [85.8-100] 1.000 
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Specificity  
Clinical-
relevant 
lesion 
Accuracy  
97.3% [85.8-99.9] 94.6% [81.8-99.3] 0.802 78.4% [61.8-90.2] 0.059 
Diagnostic performance as majority reading [95% confide ce interval]] of three independent readers. a P-values 
for comparison of combined 68Ga-DOTA-exendin-4  PET/CT + MRI and 68Ga-DOTA-exendin-4  PET/CT 
alone. b P-Values for comparison of combined  68Ga-DOTA-exendin-4  PET/CT + MRI and MRI alone. 
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